Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03105102

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

The study consists of 4 sub-studies, as follows:

* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intravenous risankizumab induction treatment in Study M16-006 or Study M15-991; * Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in participants who responded to induction treatment in Study M16-006 or Study M15-991; * Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in participants who completed Sub-study 1, Sub-study 2, another AbbVie risankizumab Crohn's disease study, or participants who responded to induction treatment in Study M16-006 or Study M15-991 with no final endoscopy due to the Covid-19 pandemic. Additional objectives are to further investigate long-term efficacy and tolerability of risankizumab; * Sub-study 4 (Open-label On Body Injector (OBI) administration and long-term extension study) to evaluate patient-reported outcomes, efficacy, safety, tolerability, and pharmacokinetics of risankizumab administered via OBI in participants who are receiving maintenance treatment with risankizumab. * OL CTE to ensure uninterrupted care in accordance with local regulations until risankizumab is commercially available for participants who completed Sub-study 3, Sub-study 4.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Crohn's Disease Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

16 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Cemic /Id# 168078, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who have entered and completed Study M16-006 or Study M15-991 or other AbbVie risankizumab Crohn's disease study.
  • Participants have completed the study M16-006 or M15-991 and have achieved clinical response.
  • Sub-Study 4:
  • Participants receiving maintenance treatment in Sub-study 3 and willing to comply with the requirements of Sub-study 4, including self-administration of sub-cutaneous injections using the on-body injector (OBI).
  • Participant has received at least 16 weeks of stable dosing with risankizumab in Sub-study 3 (i.e., no rescue within 16 weeks and participant has surpassed the 72-week mark).

Exclusion criteria

  • Participants should not be enrolled in Study M16-000 with high grade colonic dysplasia or colon cancer identified during Study M15-991, Study M16-006 or another AbbVie risankizumab Crohn's disease study if the final endoscopy was performed prior to enter Study M16-000 OR is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  • Participant who has a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of Chinese hamster ovary (CHO), OR had an adverse event (AE) during Studies M16-006, M15-991 or another AbbVie risankizumab Crohn's disease study that in the Investigator's judgment makes the participant unsuitable for this study.
  • Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-006, M15-991 or another AbbVie risankizumab Crohn's disease study.
  • Confirmed positive urine pregnancy test at the Final Visit of Study M16-006, Study M15-991 or another AbbVie risankizumab Crohn's disease study.
  • Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
  • Any active or chronic recurring infections based on the Investigator's assessment makes the participant an unsuitable candidate for the study.

Treatment and study plan

Placebo for Risankizumab SC

Drug

Placebo for Risankizumab SC Subcutaneous (SC) Injection

risankizumab IV

Drug

Risankizumab IV Intravenous (IV) infusion

Other names: ABBV-066, BI 655066, SKYRIZI

placebo for risankizumab IV

Drug

Placebo for Risankizumab IV Intravenous (IV) infusion

risankizumab SC

Drug

Risankizumab SC Subcutaneous (SC) injection

Other names: ABBV-066, BI 655066, SKYRIZI

Risankizumab On-Body Injector (OBI)

Drug

Subcutaneous (SC) injection; on-body injector (OBI)

Other names: ABBV-066, BI 655066, SKYRIZI

Primary outcomes

  1. Sub-Study 1: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    Time frame: Week 52

    The CDAI is used to evaluate disease activity in patients with Crohn's disease. The CDAI clinical remission is defined as a CDAI score of < 150.

  2. Sub-Study 1: Percentage of Participants With Endoscopic Response

    Time frame: Week 52

    Endoscopic response defined as decrease from Baseline of the induction study in Simple Endoscopic Score for Crohn's Disease (SES-CD).

  3. Sub-Study 3: Number of Participants With Adverse Events

    Time frame: Up to Week 220

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent AEs are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.

  4. Sub-Study 4: Percentage of Participants With an Observer Rating of Successful Participant Self Administration

    Time frame: Up to Week 16

    Participant who successfully completed the sequence of critical steps in the instructions for use (IFU) without errors to administer study drug via the OBI at Week 0 and 16.

  5. Sub-Study 4: Percentage of Participants who had no Potential Hazards

    Time frame: Up to Week 16

    Measured by an observer on the possible use-related hazards checklist for self-administration with OBI at Week 0 and Week 16.

  6. Sub-Study 4: Percentage of Participants Rating of Acceptability Using Self-Injection Assessment Questionnaire (SIAQ) at Weeks 0, 8, 16

    Time frame: Up to Week 16

    SIAQ evaluations consist of the PRE module, which is self-completed immediately before the first OBI self-injection at baseline, and the POST module, which is self-completed 20 to 40 min following injections at Weeks 0, 8, 16. These modules are completed by participants while alone in a quiet environment.

    Participants rate each item of the SIAQ. The ratings are later transformed to scores ranging from 0 (worst experience) to 10 (best experience). The domain score is the mean of the item scores included in the domain. Domain scores are calculated only if at least half of the domain items are completed. Item and domain scores from the PRE module are compared with the corresponding item and domain scores from the POST modules.

  7. Sub-Study 4: Percentage of Participants in CDAI Clinical Remission at Week 0, 16

    Time frame: Up to Week 16

    Clinical remission per average daily stool frequency (SF) and average daily abdominal pain (AP) score.

Secondary outcomes

  1. Sub-Study 1: Percentage of Participants With Clinical Remission

    Time frame: Week 52

    Clinical remission per average daily stool frequency (SF) and average daily AP score.

  2. Sub-Study 1: Percentage of Participants With CDAI Clinical Remission Among Participants With CDAI Clinical Remission in Week 0

    Time frame: Week 52

    The CDAI is used to evaluate disease activity in patients with Crohn's disease

  3. Sub-Study 1: Percentage of Participants With Ulcer-Free Endoscopy

    Time frame: Week 52

    Endoscopic healing was assessed using SES-CD.

  4. Sub-Study 1: Percentage of Participants With Endoscopic Remission

    Time frame: Week 52

    Endoscopic Remission is defined as SES-CD <= 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable, as scored by a central reviewer

  5. Sub-Study 1: Change From Baseline of Induction in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    Time frame: Week 52

    The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.

  6. Sub-Study 1: Percentage of Participants Who Discontinued Corticosteroid Use for 90 Days and Achieved Clinical Remission in Participants Taking Steroids at Baseline

    Time frame: Week 52

    Participants who discontinued corticosteroid use and achieved clinical remission per average daily SF and average daily AP score.

  7. Sub-Study 1: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Time frame: Week 52

    The CDAI is used to evaluate disease activity in patients with Crohn's disease.

  8. Sub-Study 1: Percentage of Participants With Stool Frequency (SF) Remission

    Time frame: Week 52

    SF Remission is defined by an average daily SF <= 2.8 and not worse than baseline.

  9. Sub-Study 1: Percentage of Participants With Abdominal Pain (AP) Remission

    Time frame: Week 52

    AP Remission is defined by an average daily AP <= 1 and not worse than baseline.

  10. Sub-Study 1: Percentage of Participants With CDAI Clinical Remission and Endoscopic Response

    Time frame: Week 52

    The CDAI is used to evaluate disease activity in patients with Crohn's disease. The CDAI clinical remission is defined as a CDAI score of < 150. Endoscopic response defined as decrease from baseline of > 50% of the induction study in Simple Endoscopic Score for Crohn's Disease (SES-CD).

  11. Sub-Study 1: Percentage of Participants With Deep Remission

    Time frame: Week 52

    Deep remission defined as participants with both clinical remission (per average daily SF and average daily AP score) and endoscopic remission (assessed using SES-CD).

  12. Sub-Study 1: Percentage of Participants With Exposure Adjusted Occurrence of CD-related Hospitalizations From Week 0 Through Week 52

    Time frame: Up to Week 52

    Participants with an event that results in admission to the hospital.

Other outcomes

  1. Sub-Study 2: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    Time frame: Week 52

    The CDAI is used to evaluate disease activity in patients with Crohn's disease. The CDAI clinical remission is defined as a CDAI score of < 150.

  2. Sub-Study 2: Percentage of Participants With Endoscopic Response

    Time frame: Week 52

    Endoscopic response defined as decrease from Baseline of the induction study in Simple Endoscopic Score for Crohn's Disease (SES-CD).

  3. Sub-Study 2: Percentage of Participants With Exposure Adjusted Occurrence of CD-related Hospitalizations From Week 0 Through Week 52

    Time frame: Up to Week 52

    Participants with an event that results in admission to the hospital.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease

Acronym: FORTIFY

Important dates

Study start
2018
Primary completion
2026
Study completion
2026
First posted
Apr 7, 2017
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.